<!doctype html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Reproductive Endocrinology - Clinical Study Note</title>
    <link rel="icon" type="image/png" sizes="48x48" href="/icons/favicon-48.png?v=20260301-logoexact1" />
    <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32.png?v=20260301-logoexact1" />
    <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16.png?v=20260301-logoexact1" />
    <link rel="apple-touch-icon" sizes="180x180" href="/icons/favicon-180.png?v=20260301-logoexact1" />
    <style>
      :root {
        --bg: #f8fbff;
        --surface: #ffffff;
        --ink: #132841;
        --muted: #556c84;
        --line: #d7e4f0;
        --brand: #8a1f53;
        --brand-soft: #fff0f7;
        --teal-soft: #eefaf6;
        --warn-soft: #fff7e8;
        --danger-soft: #fff0f0;
      }

      * {
        box-sizing: border-box;
      }

      body {
        margin: 0;
        font-family: "Segoe UI", Tahoma, Arial, sans-serif;
        color: var(--ink);
        background:
          radial-gradient(circle at 84% 8%, #ffd8eb 0%, transparent 31%),
          radial-gradient(circle at 10% 20%, #eaf4ff 0%, transparent 24%),
          var(--bg);
      }

      .wrap {
        width: min(1240px, 94vw);
        margin: 22px auto 34px;
        display: grid;
        grid-template-columns: 290px 1fr;
        gap: 16px;
      }

      .panel {
        background: var(--surface);
        border: 1px solid var(--line);
        border-radius: 16px;
        box-shadow: 0 10px 24px rgba(13, 34, 62, 0.06);
      }

      .toc {
        position: sticky;
        top: 16px;
        max-height: calc(100dvh - 32px);
        overflow: auto;
        padding: 14px;
      }

      .toc h2 {
        margin: 0 0 10px;
        color: var(--brand);
        font-size: 1rem;
      }

      .toc a {
        display: block;
        text-decoration: none;
        color: #36506c;
        border-radius: 8px;
        padding: 7px 9px;
        font-size: 13px;
      }

      .toc a:hover {
        background: #fff2f8;
        color: #78194a;
      }

      .content {
        padding: 0 0 18px;
      }

      .hero {
        padding: 20px;
        border-bottom: 1px solid var(--line);
        background: linear-gradient(160deg, #ffffff 0%, #fff2f8 56%, #eef7ff 100%);
      }

      .eyebrow {
        display: inline-flex;
        align-items: center;
        min-height: 28px;
        padding: 5px 12px;
        border-radius: 999px;
        background: var(--brand-soft);
        color: #8a1f53;
        font-size: 12px;
        font-weight: 700;
        margin-bottom: 10px;
      }

      h1 {
        margin: 0;
        color: #6d1941;
        font-size: clamp(1.42rem, 2.4vw, 2.04rem);
      }

      .subtitle {
        margin: 8px 0 0;
        color: var(--muted);
        line-height: 1.55;
      }

      .hero-layout {
        margin-top: 14px;
        display: grid;
        grid-template-columns: 1.35fr 0.95fr;
        gap: 12px;
      }

      .hero-grid {
        display: grid;
        grid-template-columns: repeat(4, minmax(0, 1fr));
        gap: 10px;
      }

      .metric {
        border: 1px solid #f0d4e3;
        border-radius: 12px;
        background: #fff;
        padding: 10px;
      }

      .metric .k {
        font-size: 11px;
        color: #7a6070;
        margin-bottom: 6px;
        text-transform: uppercase;
        letter-spacing: 0.3px;
      }

      .metric .v {
        font-size: 14px;
        color: #6d1941;
        font-weight: 700;
      }

      .hero-visual {
        border: 1px solid #f0d4e3;
        border-radius: 14px;
        background: #fff;
        padding: 10px;
        display: grid;
        gap: 8px;
      }

      .hero-visual h3 {
        margin: 0;
        font-size: 0.95rem;
        color: #6d1941;
      }

      .hero-visual p {
        margin: 0;
        font-size: 0.84rem;
        color: #5d758c;
      }

      .hero-visual svg {
        width: 100%;
        height: auto;
        display: block;
      }

      .section {
        padding: 16px 20px;
        border-bottom: 1px solid #edf3fb;
      }

      .section:last-child {
        border-bottom: none;
      }

      .section h2 {
        margin: 0 0 10px;
        color: #6d1941;
        font-size: 1.16rem;
      }

      .section p {
        margin: 0;
        color: #314860;
        line-height: 1.56;
      }

      .stack {
        margin-top: 10px;
        display: grid;
        gap: 10px;
      }

      .grid-2 {
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 10px;
      }

      .grid-3 {
        display: grid;
        grid-template-columns: repeat(3, minmax(0, 1fr));
        gap: 10px;
      }

      .box {
        border: 1px solid var(--line);
        border-radius: 12px;
        padding: 11px 12px;
        background: #fff;
      }

      .box h3 {
        margin: 0 0 7px;
        font-size: 0.97rem;
        color: #1f4061;
      }

      .box p {
        margin: 0;
      }

      .box ul {
        margin: 0 0 0 17px;
        padding: 0;
      }

      .box li {
        margin: 4px 0;
        color: #304860;
      }

      .table {
        margin-top: 8px;
        width: 100%;
        border-collapse: collapse;
        border-radius: 12px;
        border: 1px solid var(--line);
        overflow: hidden;
      }

      .table th,
      .table td {
        padding: 10px;
        text-align: left;
        font-size: 14px;
        border-bottom: 1px solid #e8eff8;
        vertical-align: top;
      }

      .table th {
        background: #fff3f8;
        color: #6d1941;
      }

      .table tr:last-child td {
        border-bottom: none;
      }

      .chips {
        margin-top: 8px;
        display: flex;
        gap: 8px;
        flex-wrap: wrap;
      }

      .chip {
        display: inline-flex;
        align-items: center;
        min-height: 30px;
        padding: 4px 10px;
        border-radius: 999px;
        border: 1px solid #d8e4f2;
        background: #f8fbff;
        color: #254764;
        font-size: 13px;
        font-weight: 600;
      }

      .callout {
        margin-top: 10px;
        border-left: 4px solid #0f766e;
        border-radius: 10px;
        background: var(--teal-soft);
        color: #175358;
        padding: 10px 12px;
      }

      .callout.warn {
        border-left-color: #b66a00;
        background: var(--warn-soft);
        color: #7c5b1d;
      }

      .callout.alert {
        border-left-color: #b91c1c;
        background: var(--danger-soft);
        color: #6d2222;
      }

      .flow {
        margin-top: 10px;
        display: grid;
        gap: 9px;
      }

      .step {
        border: 1px solid #d5e3f4;
        border-radius: 12px;
        padding: 10px 11px;
        background: #f9fcff;
      }

      .step strong {
        color: #6d1941;
      }

      .arrow {
        width: 30px;
        height: 30px;
        margin: 0 auto;
        border-radius: 999px;
        border: 1px solid #c9d8ec;
        background: #f6fbff;
        color: #456887;
        font-weight: 900;
        display: grid;
        place-items: center;
        line-height: 1;
      }

      .diagram-card {
        margin-top: 10px;
        border: 1px solid #d8e4f2;
        border-radius: 12px;
        background: #fbfdff;
        padding: 11px;
      }

      .diagram-title {
        margin: 0 0 8px;
        font-size: 0.9rem;
        color: #1d3f62;
        font-weight: 700;
      }

      .refs a {
        color: #145aa9;
        text-decoration: none;
        word-break: break-word;
      }

      .refs a:hover {
        text-decoration: underline;
      }

      @media (max-width: 1040px) {
        .wrap {
          grid-template-columns: 1fr;
        }

        .toc {
          position: static;
          max-height: none;
        }

        .hero-layout {
          grid-template-columns: 1fr;
        }

        .hero-grid {
          grid-template-columns: repeat(2, minmax(0, 1fr));
        }
      }

      @media (max-width: 760px) {
        .grid-2,
        .grid-3,
        .hero-grid {
          grid-template-columns: 1fr;
        }
      }
    </style>
  </head>
  <body>
    <div class="wrap">
      <aside class="panel toc">
        <h2>On This Page</h2>
        <a href="#pcos">1. Polycystic Ovary Syndrome</a>
        <a href="#menopause-hrt">2. Menopause and HRT</a>
        <a href="#hormonal-contraceptives">3. Hormonal Contraceptives</a>
        <a href="#male-hypogonadism">4. Male Hypogonadism</a>
        <a href="#erectile-dysfunction">5. Erectile Dysfunction</a>
        <a href="#management-recap-drill">Recap Drill</a>
        <a href="#exam-traps">6. Common Exam Traps</a>
        <a href="#quick-revision">7. Quick Revision Summary</a>
      </aside>

      <article class="panel content">
        <header class="hero">
          <span class="eyebrow">Women's &amp; Men's Health</span>
          <h1>Reproductive Endocrinology</h1>
          <p class="subtitle">
            Clinical overview and exam mastery guide covering PCOS, menopause and HRT,
            contraceptive pharmacology, male hypogonadism, and erectile dysfunction.
          </p>

          <div class="hero-layout">
            <div class="hero-grid">
              <div class="metric">
                <div class="k">PCOS Base</div>
                <div class="v">Insulin resistance + hyperandrogenism</div>
              </div>
              <div class="metric">
                <div class="k">HRT Rule</div>
                <div class="v">Add progestin if uterus present</div>
              </div>
              <div class="metric">
                <div class="k">Hypogonadism</div>
                <div class="v">Testosterone replacement</div>
              </div>
              <div class="metric">
                <div class="k">ED Trap</div>
                <div class="v">No PDE-5 with nitrates</div>
              </div>
            </div>

            <div class="hero-visual">
              <h3>Therapeutic Decision Themes</h3>
              <svg viewBox="0 0 500 220" role="img" aria-label="Reproductive endocrinology decision map">
                <rect x="0" y="0" width="500" height="220" rx="14" fill="#fbfdff" />
                <rect x="20" y="30" width="146" height="72" rx="10" fill="#fff3f8" stroke="#f0d4e3" />
                <text x="93" y="54" text-anchor="middle" font-size="13" fill="#6d1941" font-weight="700">PCOS</text>
                <text x="93" y="72" text-anchor="middle" font-size="12" fill="#7a6070">cycle control</text>
                <text x="93" y="88" text-anchor="middle" font-size="12" fill="#7a6070">androgen control</text>

                <rect x="176" y="30" width="146" height="72" rx="10" fill="#eef7ff" stroke="#d8e6f6" />
                <text x="249" y="54" text-anchor="middle" font-size="13" fill="#1f4467" font-weight="700">Menopause</text>
                <text x="249" y="72" text-anchor="middle" font-size="12" fill="#5f7488">symptom relief</text>
                <text x="249" y="88" text-anchor="middle" font-size="12" fill="#5f7488">risk screening</text>

                <rect x="332" y="30" width="146" height="72" rx="10" fill="#eefaf7" stroke="#d4ece4" />
                <text x="405" y="54" text-anchor="middle" font-size="13" fill="#1c564f" font-weight="700">Male health</text>
                <text x="405" y="72" text-anchor="middle" font-size="12" fill="#5b7a74">testosterone</text>
                <text x="405" y="88" text-anchor="middle" font-size="12" fill="#5b7a74">ED management</text>

                <rect x="20" y="128" width="458" height="68" rx="10" fill="#ffffff" stroke="#d8e4f2" />
                <text x="249" y="154" text-anchor="middle" font-size="13" fill="#2a4963" font-weight="700">
                  Match treatment to contraindications and reproductive goals
                </text>
                <text x="249" y="172" text-anchor="middle" font-size="12" fill="#45637e">
                  Safety screening often determines first-choice drug class
                </text>
              </svg>
              <p>Therapy selection changes with fertility goals, thrombosis risk, and comorbidity profile.</p>
            </div>
          </div>
        </header>

        <section class="section" id="pcos">
          <h2>1. Polycystic Ovary Syndrome (PCOS)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Pathophysiology and Features</h3>
              <ul>
                <li>Insulin resistance</li>
                <li>Hyperandrogenism</li>
                <li>Ovulatory dysfunction</li>
                <li>Clinical: irregular menses, hirsutism, acne, obesity, infertility</li>
              </ul>
            </div>
            <div class="box">
              <h3>Treatment Principle</h3>
              <ul>
                <li>Goal-directed care: cycle control vs fertility focus</li>
              </ul>
            </div>
          </div>

          <table class="table">
            <thead>
              <tr>
                <th>Drug/Class</th>
                <th>MOA</th>
                <th>Dose Regimen</th>
                <th>Side Effects</th>
                <th>Contraindications</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Combined oral contraceptives</td>
                <td>Suppress LH, reduce ovarian androgen production, regulate cycle</td>
                <td>Ethinyl estradiol 20-35 mcg plus progestin, one tablet daily (21-28 day cycle)</td>
                <td>Nausea, breast tenderness, VTE risk</td>
                <td>Prior DVT/PE, migraine with aura, uncontrolled hypertension, smoking over age 35</td>
              </tr>
              <tr>
                <td>Metformin</td>
                <td>Improves insulin sensitivity and may improve ovulation</td>
                <td>Start 500 mg daily, titrate to 1000-2000 mg/day divided</td>
                <td>GI upset, rare lactic acidosis</td>
                <td>Severe renal impairment, acute metabolic acidosis</td>
              </tr>
              <tr>
                <td>Spironolactone</td>
                <td>Androgen receptor blockade for hirsutism control</td>
                <td>50-100 mg orally twice daily</td>
                <td>Hyperkalemia, menstrual irregularity</td>
                <td>Pregnancy (teratogenic) and significant hyperkalemia risk; use reliable contraception</td>
              </tr>
            </tbody>
          </table>
        </section>

        <section class="section" id="menopause-hrt">
          <h2>2. Menopause and Hormone Replacement Therapy (HRT)</h2>
          <p>
            Indicated for severe vasomotor symptoms or genitourinary syndrome after risk assessment.
          </p>
          <table class="table">
            <thead>
              <tr>
                <th>Therapy</th>
                <th>MOA</th>
                <th>Dose Regimen</th>
                <th>Side Effects</th>
                <th>Contraindications / Rules</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Estradiol (oral or transdermal)</td>
                <td>Replaces declining estrogen</td>
                <td>Oral 0.5-2 mg daily; patch 0.025-0.1 mg/day</td>
                <td>Breast tenderness, VTE/stroke risk</td>
                <td>Contraindicated in breast cancer, prior DVT/PE, active liver disease</td>
              </tr>
              <tr>
                <td>Medroxyprogesterone (if uterus intact)</td>
                <td>Progestin endometrial protection against unopposed estrogen effect</td>
                <td>2.5-5 mg daily</td>
                <td>Mood change, bleeding pattern changes</td>
                <td>Required when uterus is present to reduce endometrial cancer risk</td>
              </tr>
            </tbody>
          </table>
        </section>

        <section class="section" id="hormonal-contraceptives">
          <h2>3. Hormonal Contraceptives</h2>
          <table class="table">
            <thead>
              <tr>
                <th>Method</th>
                <th>MOA</th>
                <th>Dose Regimen</th>
                <th>Key Notes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Combined oral contraceptive</td>
                <td>Suppresses ovulation, thickens cervical mucus, thins endometrium</td>
                <td>Ethinyl estradiol 20-35 mcg daily with progestin</td>
                <td>Use only when estrogen is safe</td>
              </tr>
              <tr>
                <td>Progestin-only pill</td>
                <td>Mainly thickens cervical mucus and alters endometrium</td>
                <td>Norethindrone 0.35 mg daily</td>
                <td>Useful during breastfeeding or estrogen contraindication</td>
              </tr>
              <tr>
                <td>Depot medroxyprogesterone (DMPA)</td>
                <td>Ovulation suppression and endometrial effect</td>
                <td>150 mg IM every 3 months</td>
                <td>Weight gain and bone density reduction can occur</td>
              </tr>
              <tr>
                <td>Levonorgestrel IUD</td>
                <td>Local progestin effect on endometrium/cervical mucus</td>
                <td>Device duration 3-8 years by product</td>
                <td>Long-acting reversible method</td>
              </tr>
            </tbody>
          </table>
        </section>

        <section class="section" id="male-hypogonadism">
          <h2>4. Male Hypogonadism</h2>
          <div class="box stack">
            <h3>Testosterone Replacement</h3>
            <ul>
              <li>MOA: restores physiologic serum testosterone</li>
              <li>IM cypionate: 50-100 mg weekly or 100-200 mg every 2 weeks</li>
              <li>Transdermal gel: 50-100 mg daily</li>
              <li>Side effects: polycythemia, acne, infertility, prostate enlargement</li>
              <li>Contraindications: prostate or breast cancer</li>
            </ul>
          </div>
        </section>

        <section class="section" id="erectile-dysfunction">
          <h2>5. Erectile Dysfunction (ED)</h2>
          <p>Most common etiology is vascular dysfunction.</p>
          <div class="box stack">
            <h3>PDE-5 Inhibitors (Sildenafil, Tadalafil)</h3>
            <ul>
              <li>MOA: PDE-5 inhibition raises cGMP and augments nitric oxide-mediated vasodilation</li>
              <li>Sildenafil dose: 50 mg about 1 hour pre-intercourse (range 25-100 mg)</li>
              <li>Side effects: headache, flushing, hypotension</li>
              <li>Contraindication: concurrent nitrate use (risk of severe hypotension)</li>
            </ul>
          </div>
        </section>

        <section class="section" id="management-recap-drill">
          <h2>Management Recap Drill</h2>
          <div class="flow">
            <div class="step"><strong>PCOS:</strong> COC first-line for cycle control, add spironolactone for hirsutism with contraception.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Menopause:</strong> estrogen with progestin when uterus is intact.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Contraception:</strong> choose COC when safe; progestin-only when estrogen unsafe.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>Hypogonadism:</strong> testosterone replacement with safety monitoring.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>ED:</strong> sildenafil class, never with nitrates.</div>
          </div>

          <div class="diagram-card">
            <p class="diagram-title">Visual Algorithm Placeholder</p>
            <p>
              [Insert Reproductive Endocrine Treatment Algorithm Here During UI Integration]
            </p>
          </div>
        </section>

        <section class="section refs">
          <h2>Guideline References (Management)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Endocrine Society Guidelines</h3>
              <a href="https://www.endocrine.org" target="_blank" rel="noopener">
                https://www.endocrine.org
              </a>
            </div>
            <div class="box">
              <h3>ACOG Guidance</h3>
              <a href="https://www.acog.org" target="_blank" rel="noopener">
                https://www.acog.org
              </a>
            </div>
          </div>
          <div class="callout">
            Core scope includes PCOS care, HRT risk-safety balance, testosterone therapy, and contraceptive eligibility.
          </div>
        </section>

        <section class="section" id="exam-traps">
          <h2>6. Common Exam Traps</h2>
          <div class="stack">
            <div class="callout alert">Do not use estrogen in migraine with aura.</div>
            <div class="callout alert">Add progestin when uterus is intact during systemic estrogen therapy.</div>
            <div class="callout alert">Exogenous testosterone suppresses fertility.</div>
            <div class="callout alert">PDE-5 inhibitors are contraindicated with nitrates.</div>
            <div class="callout alert">Spironolactone is teratogenic and requires contraception planning.</div>
          </div>
        </section>

        <section class="section" id="quick-revision">
          <h2>7. Quick Revision Summary</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Must Remember</h3>
              <ul>
                <li>PCOS centers on insulin resistance and hyperandrogenism</li>
                <li>COCs regulate cycle and reduce androgenic features</li>
                <li>HRT must account for uterus status and thrombotic risk</li>
                <li>Testosterone therapy requires adverse effect monitoring</li>
                <li>Sildenafil-class drugs cannot be combined with nitrates</li>
              </ul>
            </div>
            <div class="box">
              <h3>Practice Questions Placeholder</h3>
              <ul>
                <li>Topic: Reproductive Endocrinology</li>
                <li>
                  Subtopics: PCOS, HRT, contraception, hypogonadism, erectile dysfunction
                </li>
              </ul>
            </div>
          </div>
        </section>
      </article>
    </div>
  </body>
</html>
